Citation Impact
Citing Papers
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
2014
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
2008 StandoutScience
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance
2012
Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
2013
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent
2015
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
2014
Programming for CD8 T Cell Memory Development Requires IL-12 or Type I IFN
2009
The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
2008
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
2013
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
How chemokines organize the tumour microenvironment
2023
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
2012
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
2013
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
2013
Hepatocellular carcinoma
2018 Standout
Combination cancer immunotherapy and new immunomodulatory targets
2015
Blockade of the interleukin‐21/interleukin‐21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis
2007
T cell exhaustion
2011 Standout
Reciprocal regulation of the Il9 locus by counteracting activities of transcription factors IRF1 and IRF4
2017 StandoutNobel
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells
2007 StandoutNature
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Inflammatory bowel disease: cause and immunobiology
2007 Standout
Immunological landscape and immunotherapy of hepatocellular carcinoma
2015
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
2012
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
2015
Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation
2005
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Overcoming T cell exhaustion in infection and cancer
2015
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
2015
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Spermine Induces Maturation of the Immature Intestinal Immune System in Neonatal Mice
1997
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
The mTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin
2010
Transforming Growth Factor β-Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression
2014
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
2015
LAG-3 in Cancer Immunotherapy
2010
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
2007
Generating diversity: transcriptional regulation of effector and memory CD8+ T‐cell differentiation
2010
Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
2010
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Regulation of Interferon‐γ During Innate and Adaptive Immune Responses
2007
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
2004
Molecular and cellular insights into T cell exhaustion
2015 Standout
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
2019
Close encounters of different kinds: Dendritic cells and NK cells take centre stage
2005
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
2014
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Tumor Angiogenesis
2008 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
The cell biology of cross‐presentation and the role of dendritic cell subsets
2008
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Therapeutic Targeting of the Tumor Microenvironment
2021
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Spermidine in health and disease
2018 StandoutScience
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
2012
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
IRF4 at the crossroads of effector T‐cell fate decision
2014
IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response
2005
NK cell–mediated killing of target cells triggers robust antigen-specific T cell–mediated and humoral responses
2009 StandoutNobel
Differential Effects of Interleukin-2 and Interleukin-15 versus Interleukin-21 on CD4+ Cutaneous T-Cell Lymphoma Cells
2008
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
2011 StandoutNobel
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
De novo design of protein logic gates
2020 StandoutScienceNobel
Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses
2012 StandoutNobel
Works of Cheryl Eppolito being referenced
IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-21
2004
IL-12-Programmed Long-Term CD8+ T Cell Responses Require STAT4
2006
Regulating functional cell fates in CD8 T cells
2009
The Shiga toxin B‐subunit targets antigen in vivo to dendritic cells and elicits anti‐tumor immunity
2006
Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
2010
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
2015
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
2021
Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
1993
Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts.
1986